Predictive Biomarkers in Muscle Invasive Bladder Cancer: Are We There Yet?

Affiliations

¹ Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
² Cross Cancer Institute, Edmonton, Alberta, Canada.
³ Hematology and Medical Oncology, Centre Hospitalier Universitaire de Montreal, Montreal, Quebec, Canada.

Editorial

Srikala S Sridhar et al. Eur Urol. 2023 Apr.

. 2023 Apr;83(4):318-319.

doi: 10.1016/j.eururo.2022.09.003. Epub 2022 Sep 23.

¹ Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
² Cross Cancer Institute, Edmonton, Alberta, Canada.
³ Hematology and Medical Oncology, Centre Hospitalier Universitaire de Montreal, Montreal, Quebec, Canada.

No abstract available

Comment on

Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
Gil-Jimenez A, van Dorp J, Contreras-Sanz A, van der Vos K, Vis DJ, Braaf L, Broeks A, Kerkhoven R, van Kessel KEM, Ribal MJ, Alcaraz A, Wessels LFA, Seiler R, Wright JL, Mengual L, Boormans J, van Rhijn BWG, Black PC, van der Heijden MS. Gil-Jimenez A, et al. Eur Urol. 2023 Apr;83(4):313-317. doi: 10.1016/j.eururo.2022.07.023. Epub 2022 Aug 11. Eur Urol. 2023. PMID: 35965206